This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayden, F G Articles by Monto, A S Search for Related Content PubMed PubMed Citation Articles by Hayden, F G Articles by Monto, A S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1986 February; 29(2): 339-341

Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.

ABSTRACT

In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.

This article has been cited by other articles:

• Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., for the US Oral Neuraminidase Study Group, (2000). Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. JAMA 283: 1016-1024 [Abstract] [Full Text]  
• Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., Straus, S. E. (1999). Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment. JAMA 282: 1240-1246 [Abstract] [Full Text]  
• Hayden, F. G., Osterhaus, A. D.M.E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., Wightman, K., The GG167 Influenza Study Group, (1997). Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. NEJM 337: 874-880 [Abstract] [Full Text]